Exhibit 10(ww)
*****************************NOTICE OF GRANT AWARD*****************************
SMALL BUSINESS INNOVATION RESEARCH PROG Issue Date: 05/17/2002
Department of Health and Human Services
National Institutes Of Health
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
*******************************************************************************
Grant Number: 2 R44 A146828-02
Principal Investigator: HRUBY, DENNIS E MD
Project Title: DegP Proteinase Inhibitors: Novel Anti-Infectives
KONATICH, THOMAS
CHIEF FINANCIAL OFFICER
SIGA TECHNOLOGIES, INC
420 LEXINGTON AVE, SUITE 620
NEW YORK, NY 10170
UNITED STATES
Budget Period: 06/01/2002 - 05/31/2003
Project Period: 08/01/2000 - 05/31/2004
Dear Business Official:
The National Institutes of Health hereby awards a grant in the amount of
$529,359 (see "Award Calculation" in Section I) to SIGA TECHNOLOGIES, INC. in
support of the above referenced project. This award is pursuant to the authority
of 42 USC 241 42 CFR PART 52 15 USC 638 and is subject to terms and conditions
referenced below.
Acceptance of this award including the Terms and Conditions is acknowledged by
the grantee when funds are drawn down or otherwise obtained from the grant
payment system.
Award recipients are responsible for reporting inventions derived or reduced to
practice in the performance of work under this grant. Rights to inventions vest
with the grantee organization provided certain requirements are met and there is
acknowledgement of NIH support. In addition, recipients must ensure that patent
and license activities are consistent with their responsibility to make unique
research resources developed under this award available to the scientific
community, in accordance with NIH policy. For additional information, please
visit http://www.iedison.gov.
If you have any questions about this award, please contact the individual(s)
referenced in the information below.
Sincerely yours,
/s/ Theresa Mercogliano
- -----------------------
Theresa Mercogliano
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
See additional information below
SECTION I - AWARD DATA - 2 R44 AI46828-02
AWARD CALCULATION (U.S. Dollars):
Salaries and Wages $75,695
Personnel Costs $75,695
Equipment $105,265
Supplies $23,128
Consortium/Contractual Cost $212,730
Federal Direct Costs $416,818
Federal F&A Costs $100,036
APPROVED BUDGET $516,854
Fee $ 12,505
TOTAL FEDERAL AWARD AMOUNT $529,359
529,359
Recommended future year total cost support, subject to the availability of funds
and satisfactory progress of the project, is as follows.
03 $335,698
FISCAL INFORMATION:
CFDA Number: 93.856
EIN: ll33864870Al
Document Number: R4AI46828B
IC/ CAN / FY2002 / FY2003
AI/8425730 / 529,359 / 335,698
NIH ADMINISTRATIVE DATA:
PCC: M36 / OC: 4l.4B /Processed: MERCOGL 020514 0940
SECTION II - PAYMENT/HOTLINE INFORMATION - 2 R44 A146828-02
For Payment and HHS Office of Inspector General Hotline Information, see the NIH
Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm
SECTION III - TERMS AND CONDITIONS - 2 R44 A146828-02
This award is based on the application submitted to, and as approved by,
the NIH on the above-titled project and is subject to the terms and conditions
incorporated either directly or by reference in the following:
a. The grant program legislation and program regulation cited in this Notice of
Grant Award.
b. The restrictions on the expenditure of federal funds in appropriations acts,
to the extent those restrictions are pertinent to the award.
c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
d. The NIH Grants Policy Statement, including addenda in effect as of the
beginning date of the budget period.
e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.
(see NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm
for certain references cited above.)
An unobligated balance may be carried over into the next budget period without
Grants Management Officer prior approval.
This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).
Treatment of Program Income:
Additional Costs
The NIAID is pleased that investigators are submitting investigator-initiated
applications to conduct exciting and important clinical research on the wide
variety of infectious diseases and infectious agents of interest to the Division
of Microbiology and Infectious Diseases. The NIAID supports clinical trials and
research through grants, such as the application that you have submitted, as
well as other funding mechanisms. The NIAID also has oversight responsibilities
to ensure compliance with government regulations and facilitate the safety of
participants in these studies. To assist us in this process, any funded
applications for clinical trials will contain within the Notice of Grant Award,
a clear outline of your responsibilities. Acceptance of the competing grant
award, as referenced above, will constitute agreement with these additional
Terms of Award. http://www.niaid.nih.gov/ncn/pdf/clinterm.pdf
Briefly, as a condition of award and before the initiation of any/each planned
clinical study, you are required to submit to your program officer the following
information:
a) A copy of the protocol
b) The proposed informed consent form. You may want to use the model developed
by the NCI (URL:
http://cancertrials.nci.nih.gov/researchers/safeguards/consent/template.html)
c) A plan for monitoring the safety of study subjects
d) A plan for serious adverse event reporting, if applicable
Division staff members are available to assist with various aspects of protocol
development, particularly in the areas of informed consent, site monitoring, and
adverse events monitoring methods. We also welcome pre-enrollment meetings to
discuss details of the study.
If we can be of further assistance, please contact your Program Administrator or
your Grants Management Officer, their names are listed below.
PAYMENT INFORMATION: The awardee organization will receive information and forms
from the Payment Management System of the Department of Health and Human
Services regarding requests for cash, manners of payment, and associated
reporting requirements. Payment may be made on a cost-reimbursement or advance
basis. Cost reimbursements may be requested monthly, quarterly, or at other
periodic intervals. Advance payments may be requested on a monthly basis only.
The telephone number for the Payment Management System Office is (301) 443-1660.
The total fixed fee for your Phase II project is $20,436 and is included in the
maximum allowable total costs. This fee is incrementally funded proportionately
for each budget period. $12,505 are allotted for payment of fixed fee for the
budget period covered by this Notice of Grant Award. Additional funds for the
remainder of the total fixed fee are intended to be allotted by a future
Notice(s) of Grant Award, and is reflected in the future year total cost
commitment base on this Notice of Grant Award. Unless and until such future
Notice(s) of Grant Award is (are) issued, the Government will not be obligated
to reimburse the grantee organization for more than the funds currently allotted
for payment of the fixed fee. An adjustment of the fee will be made in the event
the grant is terminated or future support is withheld. The fee allotted under
this Notice of Grant Award is to be drawn down from the BBS Payment System in
increments proportionate to the draw down of funds for costs.
When purchasing equipment or products under this SBIR award, the grantee shall
use only American-made items whenever possible.
Intellectual property rights: Normally, the awardee organization retains the
principal worldwide patent rights to any invention developed with United States
Government support. Under Title 37 Code of Federal Regulations Part 401, the
Government receives a royalty-free license for its use, reserves the right to
require the patent holder to license others in certain circumstances, and
requires that anyone exclusively licensed to sell the invention in the United
States must normally manufacture it substantially in the United States.
Rights and obligations related to inventions created or reduced to practice as a
result of this award are detailed in 35 U.S.C. 205 and 37 CFR Part 401. These
inventions must be reported to the Extramural Invention Reporting and Technology
Resources Branch, OPERA, NIH, 6701 Rockledge Drive, MSC 7750, Bethesda, MD
20892-7750, (301) 435-1986. For additional
information, access the NIH link on the Interagency Edison web site
(www.iedison.gov) which includes an electronic invention reporting system,
reference information and the text to 37 CFR 401.
To the extent authorized by 35 U.S.C., Section 205, the Government will not make
public any information disclosing an NIH-supported invention for a 4-year period
to allow the awardee organization a reasonable time to file a patent
application, nor will the Government release any information that is part of
that patent application.
Allowable costs conducted by for-profit organizations will be determined by
applying the cost principles of Contracts with Commercial Organizations set
forth in 48 CFR, Subpart 31.2.
Marissa A Miller, Program Official
Phone: 301-496-7728 Email: mm459k@nih.gov
Theresa Mercogliano, Grants Specialist
SPREADSHEET
GRANT NUMBER: 2 R44 A146828-02
P.1.: HRUBY, DENNIS E
INSTITUTION: SIGA TECHNOLOGIES, INC.
YEAR 02 YEAR 03
======= =======
Salaries and Wages 75,695 92,213
Personnel Costs 75,695 92,213
Equipment 105,265
Supplies 23,128 52,115
Consortium/Contractual Cost 212,730 120,000
TOTAL FEDERAL DC 416,818 264,328
TOTAL FEDERAL F&A 100,036 63,439
TOTAL COST 516,854 327,767
YEAR 02 YEAR 03
======= =======
F&A Cost Rate 1 24.00% 24.00%
F&A Cost Base 1 416,818 264,328
F&A Costs 1 100,036 63,439
FEE 12,505 7,931